[go: up one dir, main page]

AR075235A1 - Derivados de indol como agentes anticancer. - Google Patents

Derivados de indol como agentes anticancer.

Info

Publication number
AR075235A1
AR075235A1 ARP100100298A ARP100100298A AR075235A1 AR 075235 A1 AR075235 A1 AR 075235A1 AR P100100298 A ARP100100298 A AR P100100298A AR P100100298 A ARP100100298 A AR P100100298A AR 075235 A1 AR075235 A1 AR 075235A1
Authority
AR
Argentina
Prior art keywords
indol
derivatives
anticancer agents
hydroxyalkyl
cancer
Prior art date
Application number
ARP100100298A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR075235A1 publication Critical patent/AR075235A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso para el tratamiento del cáncer, así como composiciones farmacéuticas para el tratamiento de cáncer, así como composiciones farmacéuticas que comprenden dichos compuestos de la formula (1) y el proceso de preparacion. Reivindicacion 1: Un compuesto de la formula (1) incluyendo cualquiera de sus formas estereoquímicamente isoméricas, en donde R1es hidroxialquilo C1-6 o alquenilo C2-6; siempre que el sustituyente R1 esté ubicado en la posicion 6 o 7 del resto indol; R2 es hidrogeno o alquilo C1-4; Z es un radical seleccionado de las formulas (2) o (3); R3 es hidrogeno o hidroxialquilo C1-4; R4 es hidroxi o alquiloxi C1-4; R5 H o alquilo C1-4; o R4 y R5 se toman juntos para formar oxo; una de sus sales farmacéuticamente aceptables o uno de sus solvatos.
ARP100100298A 2009-02-04 2010-02-03 Derivados de indol como agentes anticancer. AR075235A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09152089 2009-02-04

Publications (1)

Publication Number Publication Date
AR075235A1 true AR075235A1 (es) 2011-03-16

Family

ID=40738626

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100298A AR075235A1 (es) 2009-02-04 2010-02-03 Derivados de indol como agentes anticancer.

Country Status (23)

Country Link
US (1) US8541442B2 (es)
EP (1) EP2393801B1 (es)
JP (1) JP5612611B2 (es)
KR (1) KR101730407B1 (es)
CN (1) CN102307868B (es)
AR (1) AR075235A1 (es)
AU (1) AU2010210178B2 (es)
BR (1) BRPI1008855B8 (es)
CA (1) CA2749209C (es)
CL (1) CL2011001860A1 (es)
CO (1) CO6341625A2 (es)
EA (1) EA021883B1 (es)
ES (1) ES2639752T3 (es)
IL (1) IL214427A (es)
MX (1) MX2011008195A (es)
MY (1) MY152018A (es)
NO (1) NO20111199A1 (es)
NZ (1) NZ594186A (es)
SG (1) SG173495A1 (es)
TW (1) TWI476189B (es)
UA (1) UA107455C2 (es)
WO (1) WO2010089327A2 (es)
ZA (1) ZA201105695B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2841517B2 (ja) 1989-08-11 1998-12-24 株式会社ツムラ 入浴剤
JP2872763B2 (ja) 1990-06-28 1999-03-24 紀伊産業株式会社 携帯用肛門洗浄器
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
CN106632303A (zh) * 2017-01-09 2017-05-10 湖南华腾制药有限公司 一种6‑噻唑基吲哚衍生物的制备方法
CN111587249A (zh) 2017-11-20 2020-08-25 阿里根公司 吲哚化合物及其用途
CN108659003B (zh) * 2018-04-14 2021-01-26 上海朝晖药业有限公司 一种治疗口腔溃疡的化合物的制备方法
EP3907218A4 (en) * 2019-01-04 2022-09-21 Jiangsu Hengrui Medicine Co., Ltd. 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, METHOD FOR PREPARATION AND MEDICAL USE
KR20210131357A (ko) * 2019-02-20 2021-11-02 지앙수 헨그루이 메디슨 컴퍼니 리미티드 6-옥소-1,6-디하이드로피리다진 프로드러그 유도체, 이의 제조 방법, 및 의약에서의 이의 응용
AU2020258394A1 (en) 2019-04-15 2021-10-28 Ariagen, Inc. Chiral indole compounds and their use
WO2024102758A2 (en) * 2022-11-08 2024-05-16 The General Hospital Corporation N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP2002531396A (ja) 1998-12-02 2002-09-24 ファイザー・プロダクツ・インク ｐ５３ファミリーのタンパク質の配座安定性を回復するための方法及び組成物
WO2001042224A1 (en) 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
SG126006A1 (en) 2000-09-15 2006-10-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
PT1859798E (pt) * 2001-03-29 2016-03-31 Lilly Co Eli N-(2-ariletil)benzilaminas como antagonistas do receptor 5-ht6
US20030149038A1 (en) 2001-11-09 2003-08-07 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
PL370176A1 (en) 2001-11-13 2005-05-16 3-Dimensional Pharmaceuticals, Inc. Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CN100486969C (zh) 2001-12-18 2009-05-13 霍夫曼-拉罗奇有限公司 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
KR101331786B1 (ko) * 2004-09-22 2013-11-21 얀센 파마슈티카 엔.브이. Ｍｄｍ2 및 ｐ53간의 상호작용 저해제
EP2001868B1 (en) * 2006-03-22 2013-07-17 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
US8088795B2 (en) 2006-03-22 2012-01-03 Janssen Pharmaceutica N.V. Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53
US20100129933A1 (en) * 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
WO2009019274A1 (en) * 2007-08-06 2009-02-12 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
AU2008300483B2 (en) 2007-09-21 2013-01-10 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and p53

Also Published As

Publication number Publication date
AU2010210178B2 (en) 2014-06-05
KR101730407B1 (ko) 2017-04-26
BRPI1008855B8 (pt) 2021-05-25
SG173495A1 (en) 2011-09-29
CA2749209C (en) 2017-01-10
UA107455C2 (uk) 2015-01-12
ZA201105695B (en) 2014-01-29
CO6341625A2 (es) 2011-11-21
MY152018A (en) 2014-08-15
WO2010089327A3 (en) 2010-10-21
WO2010089327A2 (en) 2010-08-12
CL2011001860A1 (es) 2012-07-20
TWI476189B (zh) 2015-03-11
NZ594186A (en) 2012-12-21
BRPI1008855A2 (pt) 2016-03-15
KR20110116195A (ko) 2011-10-25
AU2010210178A1 (en) 2011-07-28
BRPI1008855B1 (pt) 2020-05-12
IL214427A (en) 2016-02-29
JP5612611B2 (ja) 2014-10-22
EA021883B1 (ru) 2015-09-30
IL214427A0 (en) 2011-09-27
JP2012516872A (ja) 2012-07-26
CA2749209A1 (en) 2010-08-12
CN102307868A (zh) 2012-01-04
US20110294846A1 (en) 2011-12-01
NO20111199A1 (no) 2011-11-04
MX2011008195A (es) 2011-09-06
US8541442B2 (en) 2013-09-24
EA201170997A1 (ru) 2012-01-30
ES2639752T3 (es) 2017-10-30
TW201038552A (en) 2010-11-01
EP2393801A2 (en) 2011-12-14
EP2393801B1 (en) 2017-07-12
CN102307868B (zh) 2016-06-22

Similar Documents

Publication Publication Date Title
AR075235A1 (es) Derivados de indol como agentes anticancer.
AR082826A2 (es) Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos
CR10712A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales
ECSP088114A (es) Nuevos derivados de la 2-azetidinona y su uso como inhibidores de absorción del colesterol para el tratamiento de hiperlipidemia
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CO6251271A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY29702A1 (es) Inhibidores macrocíclicos del virus de hepatitis c
CO7400872A2 (es) Derivados sustituidos de ftalazin-1(2h)-ona
AR087182A1 (es) DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
AR078722A1 (es) Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol
CL2012000925A1 (es) Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras.
AR071857A1 (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AR090955A1 (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih
CL2021002110A1 (es) Hidroxipiridoxazepinas como activadores de nrf2.
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
AR060427A1 (es) Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
AR081966A1 (es) Derivados aminoester de alcaloides y composicion medicinal de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure